Purpose of review: CD19-directed chimeric antigen receptor (CAR) T-cell therapy is a valuable new treatment option for patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma. The aim of this review is to give an overview of the pivotal phase I/II trials, emerging real-world evidence and ongoing trials. Recent findings: For decades, attempts at improvement of the poor prognosis of patients with R/R large
The COVID-19 pandemic has rapidly changed delivery of cancer care. Many nonurgent surgeries are delayed to preserve hospital resources, and patient visits to health care settings are limited to reduce exposure to SARS-CoV-2. Providers must carefully weigh risks and benefits of delivering immunosuppressive therapy during the pandemic. For breast cancer, a key difference is increased use of neoadjuvant systemic therapy due
Background: Since the outbreak of novel coronavirus disease (COVID-19) in Wuhan, China at the beginning of December 2019, there have been over 11,200,000 confirmed cases in the world as of the 3rd July 2020, affecting over 213 countries and regions with nearly 530,000 deaths. The pandemic has been sweeping all continents, North America, Latin America, Europe, Middle East and South
The lockdown measures of the ongoing COVID-19 pandemic have disengaged patients with cancer from formal health care settings, leading to an increased use of social media platforms to address unmet needs and expectations. Although remote health technologies have addressed some of the medical needs, the emotional and mental well-being of these patients remain underexplored and underreported. We used a validated artificial intelligence
I pazienti con NSCLC metastatico e mutazione di METex14 ottengono un tasso di risposta positivo e duraturo a seguito del trattamento con l’inibitore di MET capmatinib.
L’analisi delle attività di erogazione dei farmaci ai pazienti in dimissione permette d’intercettare le non conformità emerse e intraprendere, così, importanti e mirate azioni di miglioramento.
I pazienti italiani colpiti da cancro hanno accesso a un numero maggiore di nuovi farmaci oncologici (33 nel periodo 2015-2018) rispetto alla media europea e in tempi più brevi.
